Get started
222

ABBISKO CAYMAN LTD

No trades
See on Supercharts
Overview
Financials News Discussions Technicals Forecast Seasonals

2256 chart


Full chart

2256 upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪3.34 B‬ HKD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.00 HKD
Net income (FY)
‪−476.90 M‬ HKD
Revenue (FY)
‪21.06 M‬ HKD
Shares float
‪446.95 M‬
Beta (1Y)
1.19

Employees


Employees (FY)
258
Change (1Y)
+8 +3.20%
Revenue / Employee (1Y)
‪10.45 K‬ HKD
Net income / Employee (1Y)
‪−236.66 K‬ HKD

About ABBISKO CAYMAN LTD


Sector
Health Technology
CEO
Yao Chang Xu
Headquarters
Shanghai
Website
abbisko.com
Founded
2016
FIGI
BBG012R769D9
Abbisko Cayman Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of drugs and small molecule oncology therapies. The firm designed and developed a pipeline of fourteen candidates focused on oncology, including six candidates at clinical stage. Its product candidates are primarily small molecules that focus on small molecule precision oncology and small molecule immuno-oncology therapeutic areas. The company was founded by Yao Chang Xu, Hong Ping Yu, and Zhui Chen on April 12, 2016 and is headquartered in Shanghai, China.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

2256 news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of 2256 is 4.92 HKD — it has increased by 11.56% in the past 24 hours. Watch ABBISKO CAYMAN LTD stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on HKEX exchange ABBISKO CAYMAN LTD stocks are traded under the ticker 2256.
2256 stock has risen by 18.55% compared to the previous week, the month change is a 26.15% rise, over the last year ABBISKO CAYMAN LTD has showed a 29.47% increase.
We've gathered analysts' opinions on ABBISKO CAYMAN LTD future price: according to them, 2256 price has a max estimate of 8.48 HKD and a min estimate of 8.48 HKD. Watch 2256 chart and read a more detailed ABBISKO CAYMAN LTD stock forecast: see what analysts think of ABBISKO CAYMAN LTD and suggest that you do with its stocks.
2256 reached its all-time high on Nov 5, 2021 with the price of 12.54 HKD, and its all-time low was 2.05 HKD and was reached on Feb 15, 2024. View more price dynamics on 2256 chart.
See other stocks reaching their highest and lowest prices.
2256 stock is 13.00% volatile and has beta coefficient of 1.19. Track ABBISKO CAYMAN LTD stock price on the chart and check out the list of the most volatile stocks — is ABBISKO CAYMAN LTD there?
Yes, you can track ABBISKO CAYMAN LTD financials in yearly and quarterly reports right on TradingView.
ABBISKO CAYMAN LTD is going to release the next earnings report on Mar 13, 2025. Keep track of upcoming events with our Earnings Calendar.
2256 earnings for the last half-year are 0.34 HKD per share, whereas the estimation was 0.27 HKD, resulting in a 28.00% surprise. The estimated earnings for the next half-year are −0.54 HKD per share. See more details about ABBISKO CAYMAN LTD earnings.
ABBISKO CAYMAN LTD revenue for the last half-year amounts to ‪534.29 M‬ HKD, despite the estimated figure of ‪533.99 M‬ HKD. In the next half-year revenue is expected to reach 0.00 HKD.
2256 net income for the last half-year is ‪224.08 M‬ HKD, while the previous report showed ‪−240.91 M‬ HKD of net income which accounts for 193.02% change. Track more ABBISKO CAYMAN LTD financial stats to get the full picture.
No, 2256 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 10, 2024, the company has 258.00 employees. See our rating of the largest employees — is ABBISKO CAYMAN LTD on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ABBISKO CAYMAN LTD EBITDA is ‪−18.99 M‬ HKD, and current EBITDA margin is ‪−2.58 K‬%. See more stats in ABBISKO CAYMAN LTD financial statements.
Like other stocks, 2256 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ABBISKO CAYMAN LTD stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ABBISKO CAYMAN LTD technincal analysis shows the strong buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ABBISKO CAYMAN LTD stock shows the strong buy signal. See more of ABBISKO CAYMAN LTD technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.